Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DZD9008 in Non-Hodgkin B-cell Lymphoma
NCT04148742Phase 2Withdrawn
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- Aug 2021
- Primary completion
- Jul 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunvozertinib in B-cell non-Hodgkin lymphoma, sponsored by Dizal Pharmaceutical Co., Ltd. Primary endpoints: Incidence of Treatment-Emergent Adverse Events and Objective Response Rate. Planned start Aug 2021; status: withdrawn.
02
Drugs
sunvozertinib
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT04148742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04148742.